Clinical Trial Detail

NCT ID NCT03901469
Title A Study of ZEN003694 and Talazoparib in Patients With Triple Negative Breast Cancer (TNBC)
Recruitment Recruiting
Gender both
Phase Phase II
Variant Requirements No
Sponsors Zenith Epigenetics
Indications

triple-receptor negative breast cancer

Therapies

Talazoparib + ZEN-3694

Age Groups: senior adult

No variant requirements are available.